Systematic identification of genomic markers of drug sensitivity in cancer cells
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers of response to targeted agents. To uncover new biomarkers of sensitivity and resistance to cancer therapeutics, we screened a panel of several hundred ca...
Similar Items
-
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
by: Gill, Sonja J., et al.
Published: (2015) -
A Landscape of Pharmacogenomic Interactions in Cancer
by: Iorio, Francesco, et al.
Published: (2016) -
A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation
by: Nelson, Erik A., et al.
Published: (2011) -
Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1
by: Deng, Xianming, et al.
Published: (2011) -
Rho-kinase regulates tissue morphogenesis via non-muscle myosin and LIM-kinase during Drosophila development
by: Verdier, Valerie, et al.
Published: (2006)